Earnings Call InsightsAssertio outlines $110M–$125M 2026 revenue target with Rolvedon at the core while shifting business development approachMar. 16, 2026 6:03 PM ETAssertio Holdings, Inc. (ASRT) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Assertio Holdings, Inc. (ASRT) Q4 2025 Management View CEO Mark L. Reisenauer emphasized a shift in Assertio’s growth strategy, stating the company will prioritize driving "significant revenue opportunity in our core asset, Rolvedon," and tha ...

Assertio (NasdaqCM:ASRT) Q4 2025 Earnings call March 16, 2026 04:30 PM ET Speaker4Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings Fourth Quarter and Full Year 2025 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during th ...

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Share Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026 LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the "Company†) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated product ...

Core Insights - Assertio Holdings reported strong financial results for Q3 2025, with significant growth in net product sales, particularly for Rolvedon, which saw sales increase to $38.6 million from $15.0 million year-over-year [7][2] - The company has narrowed its FY2025 net product sales guidance to a range of $110 million to $112 million and adjusted EBITDA guidance to $14 million to $16 million [5][1] - Paul Schwichtenberg has been promoted to President and COO, indicating a strategic focus on operational efficiency and commercial execution [6][8] Financial Performance - Rolvedon net product sales reached $38.6 million in Q3 2025, a 157% increase from $15.0 million in Q3 2024 [7] - Sympazan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior-year quarter [7] - Indocin net product sales decreased to $4.8 million in Q3 2025 from $5.7 million in Q3 2024 due to generic competition [7] - Gross margin was reported at 72%, down from 74% in the prior-year quarter, attributed to a higher proportion of Rolvedon sales [7] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in Q3 2024 [7] Guidance and Outlook - The updated guidance for FY2025 reflects the impact of the Rolvedon pull-forward and improved visibility into expected performance for the remainder of the year [5][2] - The company expects uninterrupted patient supply of Rolvedon, with regular sales of the newly labeled product anticipated to begin in Q2 2026 [7] Leadership Changes - Paul Schwichtenberg's promotion to President and COO is aimed at enhancing commercial strategies and driving future growth [8][6] - Schwichtenberg has a history of leadership roles within the company, focusing on operational and commercial execution [8]

Core Insights - Assertio Holdings, Inc. reported total net product sales of $28.8 million for the second quarter of 2025, a decrease from $30.7 million in the same period last year [1][3] - The company narrowed its guidance for net product sales and adjusted EBITDA for the full year, reflecting first-half performance and operational efficiencies [9] Financial Performance - Net product sales for the first half of 2025 totaled $54.8 million, down from $62.6 million in the first half of 2024 [3] - The net loss for the second quarter was $16.4 million, compared to a net loss of $3.7 million in the prior year quarter [3][20] - Adjusted EBITDA for the second quarter was $5.6 million, an increase from $3.1 million in the prior year quarter [3][20] Product Performance - Rolvedon achieved net product sales of $16.1 million, up from $15.1 million in the prior year quarter, driven by higher volume and favorable adjustments [6] - Sympazan's net product sales increased to $3.2 million from $2.7 million, attributed to additional sales support [6] - Indocin's net product sales decreased to $3.0 million from $6.9 million due to generic competition [6] Cost Management - Selling, general and administrative (SG&A) expenses decreased to $17.0 million from $18.4 million, aided by a one-time benefit from employee retention tax credits [6] - The company is streamlining operations and consolidating products from acquired subsidiaries to optimize costs [2][14] Balance Sheet and Cash Flow - As of June 30, 2025, cash and investments totaled $98.2 million, up from $87.3 million at the end of the first quarter [5] - The company reported a debt of $40.0 million, consisting of 6.5% convertible notes with no maturities until September 2027 [7] Strategic Initiatives - Assertio has ceased commercialization of Otrexup to focus on core growth assets and improve operating expenses [14] - The company plans to present new data on Sympazan at the American Neurological Association Annual Meeting in September [14]

Financial Performance & Outlook - The company's Q1 2025 net product sales were $26 million[27] - The company's Q1 2025 non-GAAP adjusted EBITDA was $02 million[27] - The company's Q1 2025 operating cash flow was -$125 million[27] - The company anticipates full-year 2025 net product sales of $108-123 million[27] - The company anticipates full-year 2025 non-GAAP adjusted EBITDA of $10-19 million[27] Strategic Priorities - The company is focused on a "Transformation" phase to catalyze future growth potential[28, 29] - The company aims to simplify its corporate structure and processes[28, 29, 36] - The company intends to divest declining or non-core assets[28, 29, 36] - The company will prioritize investment in growth assets like Rolvedon and Sympazan[28, 29, 36] - The company seeks to reduce legal exposure[28, 29, 36] - The company plans to use its balance sheet to close a strategic transaction[28, 29, 36]